产品
编 号：F193974
分子式：C17H18KN3O3S
分子量：383.51
分子式：C17H18KN3O3S
分子量：383.51
产品类型
规格
价格
是否有货
结构图
CAS No: 161796-84-5
产品详情
生物活性：
Esomeprazole potassium salt ((S)-Omeprazole potassium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole potassium salt has the potential for symptomatic gastroesophageal reflux disease research.
体内研究：
Esomeprazole (30-300 mg/kg; oral gavage; daily; for 19 or 11 days; C57BL/6J mice) treatment significantly inhibits the progression of fibrosis throughout the lungs of the animals. Esomeprazole also reduces circulating markers of inflammation and fibrosis.Animal Model:C57BL/6J mice (8-weeks old, 25-30 g) treated with cotton smoke-induced lung injury
Dosage:30 mg/kg, 300 mg/kg
Administration:Oral gavage; daily; for 19 or 11 days
Result:Significantly inhibited the progression of fibrosis throughout the lungs of the animals.
体外研究：
Esomeprazole (25-100 μM; 20 hours; MDA-MB-468 cells) treatment suppresses growth of triple-negative breast cancer cell in vitro in a dose-dependent manner through increase in their intracellular acidification.
Esomeprazole potassium salt ((S)-Omeprazole potassium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole potassium salt has the potential for symptomatic gastroesophageal reflux disease research.
体内研究：
Esomeprazole (30-300 mg/kg; oral gavage; daily; for 19 or 11 days; C57BL/6J mice) treatment significantly inhibits the progression of fibrosis throughout the lungs of the animals. Esomeprazole also reduces circulating markers of inflammation and fibrosis.Animal Model:C57BL/6J mice (8-weeks old, 25-30 g) treated with cotton smoke-induced lung injury
Dosage:30 mg/kg, 300 mg/kg
Administration:Oral gavage; daily; for 19 or 11 days
Result:Significantly inhibited the progression of fibrosis throughout the lungs of the animals.
体外研究：
Esomeprazole (25-100 μM; 20 hours; MDA-MB-468 cells) treatment suppresses growth of triple-negative breast cancer cell in vitro in a dose-dependent manner through increase in their intracellular acidification.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备